{ "id": 411686, "name": "CLARENCE KASIN et al., Plaintiffs-Appellants, v. OSCO DRUG, INC., Defendant-Appellee", "name_abbreviation": "Kasin v. Osco Drug, Inc.", "decision_date": "2000-04-12", "docket_number": "No. 2 \u2014 99 \u2014 0356", "first_page": "823", "last_page": "829", "citations": [ { "type": "official", "cite": "312 Ill. App. 3d 823" } ], "court": { "name_abbreviation": "Ill. App. Ct.", "id": 8837, "name": "Illinois Appellate Court" }, "jurisdiction": { "id": 29, "name_long": "Illinois", "name": "Ill." }, "cites_to": [ { "cite": "307 Ill. App. 3d 721", "category": "reporters:state", "reporter": "Ill. App. 3d", "case_ids": [ 173594 ], "year": 1999, "pin_cites": [ { "page": "726" } ], "opinion_index": 0, "case_paths": [ "/ill-app-3d/307/0721-01" ] }, { "cite": "165 Ill. App. 3d 135", "category": "reporters:state", "reporter": "Ill. App. 3d", "case_ids": [ 3615288 ], "year": 1988, "opinion_index": 0, "case_paths": [ "/ill-app-3d/165/0135-01" ] }, { "cite": "248 Ill. App. 3d 328", "category": "reporters:state", "reporter": "Ill. App. 3d", "case_ids": [ 2943465 ], "year": 1993, "opinion_index": 0, "case_paths": [ "/ill-app-3d/248/0328-01" ] }, { "cite": "117 Ill. 2d 507", "category": "reporters:state", "reporter": "Ill. 2d", "case_ids": [ 5545405 ], "weight": 2, "year": 1987, "pin_cites": [ { "page": "517" }, { "page": "519" } ], "opinion_index": 0, "case_paths": [ "/ill-2d/117/0507-01" ] }, { "cite": "298 Ill. App. 3d 495", "category": "reporters:state", "reporter": "Ill. App. 3d", "case_ids": [ 1073692 ], "year": 1998, "pin_cites": [ { "page": "500" } ], "opinion_index": 0, "case_paths": [ "/ill-app-3d/298/0495-01" ] }, { "cite": "251 Ill. App. 3d 529", "category": "reporters:state", "reporter": "Ill. App. 3d", "case_ids": [ 2959943 ], "year": 1993, "pin_cites": [ { "page": "534" } ], "opinion_index": 0, "case_paths": [ "/ill-app-3d/251/0529-01" ] }, { "cite": "174 Ill. 2d 513", "category": "reporters:state", "reporter": "Ill. 2d", "case_ids": [ 223621 ], "year": 1996, "pin_cites": [ { "page": "530" } ], "opinion_index": 0, "case_paths": [ "/ill-2d/174/0513-01" ] }, { "cite": "153 Ill. 2d 26", "category": "reporters:state", "reporter": "Ill. 2d", "case_ids": [ 4738245 ], "weight": 7, "year": 1992, "pin_cites": [ { "page": "31" }, { "page": "34" }, { "page": "32" }, { "page": "33" }, { "page": "34" }, { "page": "33" } ], "opinion_index": 0, "case_paths": [ "/ill-2d/153/0026-01" ] } ], "analysis": { "cardinality": 635, "char_count": 14148, "ocr_confidence": 0.771, "pagerank": { "raw": 9.216274004829818e-08, "percentile": 0.5100731741503076 }, "sha256": "477c208740c5513039fe75a6cd42778c120aa9ecc2026901f53bfa178de44c9e", "simhash": "1:539fc681791f16be", "word_count": 2271 }, "last_updated": "2023-07-14T15:51:04.567640+00:00", "provenance": { "date_added": "2019-08-29", "source": "Harvard", "batch": "2018" }, "casebody": { "judges": [], "parties": [ "CLARENCE KASIN et al., Plaintiffs-Appellants, v. OSCO DRUG, INC., Defendant-Appellee." ], "opinions": [ { "text": "PRESIDING JUSTICE BOWMAN\ndelivered the opinion of the court:\nPlaintiffs, Clarence and Paul Kasin, brought a negligence action in the circuit court of Lake County against defendants, Dr. James A.\n\u2022 Gross and Oseo Drug, Inc. (Oseo). Subsequently, Dr. Gross was dismissed with prejudice. As to Oseo, plaintiffs alleged that in dispensing the prescription drug Daypro Oseo had negligently advised Clarence Kasin of the side effects of the drug when it failed to advise him \u201cof symptoms to be aware of and possible injury to kidneys and possible renal failure.\u201d As a result of taking the drug, Clarence Kasin suffered kidney failure, necessitating a kidney transplant from his brother, Paul Kasin.\nOseo filed a motion for summary judgment, arguing that, pursuant to the \u201clearned intermediary doctrine,\u201d it owed no duty to warn of side effects of a prescription drug. Additionally, Oseo argued that its voluntary undertaking to warn of some side effects of a drug did not create a duty to warn of all side effects. The trial court granted Osco\u2019s motion and entered summary judgment in its favor. Plaintiffs filed a timely notice of appeal.\nOn appeal plaintiffs contend that the trial court erred in granting summary judgment in favor of Oseo because (1) Osco\u2019s voluntary undertaking to provide an information or warning sheet with the prescription drug Daypro removed it from the protection of the learned intermediary doctrine and (2) by voluntarily undertaking to warn of certain side effects of Daypro, Oseo became obligated to warn of all side effects of the drug.\nOn or about May 23, 1995, Clarence Kasin visited Dr. James Gross for treatment of a swollen right ankle. Kasin had never previously seen Dr. Gross. Prior to his visit to Dr. Gross, Kasin had had no health problems and had received no medical treatment for nearly 25 years except for flu in March 1995. As a result, Kasin had no medical history.\nDr. Gross prescribed Daypro to reduce the swelling in Kasin\u2019s ankle. Kasin had the prescription filled at the Oseo pharmacy in Round Lake Beach. When he received his medication, he also received and read an information sheet about the medication. That sheet included the following information:\n\u201cCOMMON USES OF THIS DRUG:\nFor arthritic conditions, pain, inflammation, fever.\nHOW SHOULD I TAKE IT?\nTake with food or antacid to reduce stomach upset. Avoid alcohol or aspirin. Follow doctor\u2019s instructions. Report other drugs you take/diseases you have.\nARE THERE ANY SIDE EFFECTS?\nVery unlikely, but report: Eye/ear problems, change in urine color, bloody stools, difficulty breathing, mental changes.\u201d\nNo discussion occurred between Kasin and the pharmacist regarding the side effects or risks associated with Daypro. At his deposition, Kasin acknowledged that he relied on his doctor rather than on Oseo to advise him of any risks associated with taking the drug.\nKasin took Daypro for 10 days. During the first nine days, he experienced no side effects and felt normal. On approximately the tenth day, Kasin noticed that he lacked energy and that his stools were black. Later that day, Kasin collapsed. He was taken to Harvard Community Hospital and then transported to Condell Medical Center, where he was diagnosed with three ulcers and renal failure. At Con-dell, Kasin learned for the first time that he had been born with only one functioning kidney, which had now failed. Kasin was placed on dialysis and, subsequently, underwent a kidney transplant in December 1995. Kasin\u2019s brother, Paul, provided the donated kidney.\nOn May 27, 1997, plaintiffs filed their negligence action. Subsequently, Oseo filed its motion for summary judgment, which the trial court granted. This appeal ensued.\nThe purpose of summary judgment is not to try an issue of fact but to determine if one exists. Frye v. Medicare-Glaser Corp., 153 Ill. 2d 26, 31 (1992). Summary judgment should be granted when the pleadings, depositions, and admissions on file, together with the affidavits presented, show that there is no genuine issue of material fact and the moving party is entitled to judgment as a matter of law. Cramer v. Insurance Exchange Agency, 174 Ill. 2d 513, 530 (1996). The existence of a duty owed by the defendant to a plaintiff is a question of law that may be determined on a motion for summary judgment. Jacob v. Greve, 251 Ill. App. 3d 529, 534 (1993). This court\u2019s review of the trial court\u2019s ruling on a summary judgment is de novo. Country Mutual Insurance Co. v. Hagan, 298 Ill. App. 3d 495, 500 (1998).\nPlaintiffs first contend that Osco\u2019s voluntary undertaking to provide an information or a warning sheet with a prescription drug removed it from the protection of the learned intermediary doctrine. The learned intermediary doctrine provides that manufacturers of prescription drugs have a duty to warn prescribing physicians of a drug\u2019s known dangerous propensities and that physicians, in turn, using their medical judgment, have a duty to convey the warnings to their patients. Kirk v. Michael Reese Hospital & Medical Center, 117 Ill. 2d 507, 517 (1987). The doctrine precludes the imposition of a duty upon drug manufacturers to warn patients directly. Kirk, 117 Ill. 2d at 519. The doctrine also has been applied to exempt pharmacies and pharmacists from giving warnings to patients. See Fakhouri v. Taylor, 248 Ill. App. 3d 328 (1993); Leesley v. West, 165 Ill. App. 3d 135 (1988).\nPlaintiffs concede that absent Osco\u2019s voluntary undertaking it would have been shielded from liability by the learned intermediary doctrine but argue that because Oseo voluntarily undertook to warn of some side effects of Daypro it was removed from the protection of the doctrine. Conversely, Oseo maintains that pursuant to our supreme court\u2019s decision in Frye v. Medicare-Glaser Corp., 153 Ill. 2d 26 (1992), it was protected by the doctrine.\nIn Frye a pharmacist voluntarily undertook to affix to a prescription drug a label warning that the medicine might cause drowsiness. The plaintiff sued both the pharmacy and the pharmacist under a voluntary undertaking theory of liability. The plaintiff acknowledged that neither the pharmacy nor the pharmacist had the duty to warn of the dangerous side effects of the medication but argued that once they undertook to warn of dangerous side effects they undertook to warn of all potential dangers involved in taking the drug. The supreme court rejected plaintiffs argument and found that the defendants\u2019 liability depended upon the extent of their undertaking.\nOseo asserts that the court in Frye determined that a pharmacist was still protected by the learned intermediary doctrine even though the pharmacist offered a warning to a consumer of a drug\u2019s dangerous propensities. To support this assertion Oseo relies on a statement made by the Frye court, in dicta. The statement followed the court\u2019s rejection of the plaintiffs argument that the pharmacist\u2019s placement of a \u201cdrowsy eye\u201d label on the prescription drug container might mislead a consumer into believing that drowsiness was the only side effect of the drug. The court stated:\n\u201cIn our opinion, consumers should principally look to their prescribing physician to convey the appropriate warnings regarding drugs, and it is the prescribing physician\u2019s duty to convey these warnings to patients.\u201d Frye, 153 Ill. 2d at 34.\nIn so stating, the court made no reference to the learned intermediary doctrine. Given the context in which the statement was made, we are not persuaded that the statement indicated that the court had concluded that a pharmacist is protected by the learned intermediary doctrine even if the pharmacist voluntarily undertakes to warn a consumer of some side effects.\nOther portions of the court\u2019s opinion actually support an opposite conclusion. In particular, the court\u2019s explanation of the voluntary undertaking theory of liability and its citation of section 323 of the Restatement (Second) of Torts (Restatement (Second) of Torts \u00a7 323 (1965)), which espouses that theory (see Frye, 153 Ill. 2d at 32), suggest that the court believed that, once a pharmacist voluntarily undertook to warn a consumer of the dangerous side effects of a prescription drug, the pharmacist removed himself from the protection of the learned intermediary doctrine, thereby becoming liable for any harm to the consumer that resulted from the pharmacist\u2019s negligent performance of his voluntary undertaking. We believe the Frye opinion implies that the learned intermediary doctrine does not apply once a pharmacist voluntarily undertakes to warn a consumer of a drug\u2019s dangerous propensities. Nonetheless, under Frye, the duty the pharmacist assumes is limited to the extent of the undertaking, which is correlative to the learned intermediary doctrine\u2019s premise that the patient is dependent on the physician\u2019s rather than the pharmacist\u2019s advice and warnings. We believe Frye is determinative in the present case.\nPlaintiffs contend that, by voluntarily undertaking to warn of certain side effects of Daypro, Oseo assumed a duty to warn of all side effects of the drug. In Frye, the pharmacist affixed to the patient\u2019s prescription bottle a label warning that the medication Fiorinal could cause drowsiness. This was depicted by a label showing a drowsy eye and the statement \u201cMay Cause Drowsiness.\u201d No other labels warning of any other potential side effects were affixed to the container. The plaintiff alleged that the defendants, the pharmacist and pharmacy, failed to adequately warn of the dangerous side effects of Fiorinal because the warning label should have warned that anyone taking the drug should avoid the use of alcohol. The consumer allegedly died from the combined use of alcohol and Fiorinal.\nPlaintiffs argued that, based on the theory of negligent performance of a voluntary undertaking, the defendants had a duty to warn the decedent of all potential side effects of Fiorinal once they chose to warn him of the drug\u2019s propensity to cause drowsiness. The supreme court disagreed, finding that the defendants\u2019 duty of care was limited to the extent of their undertaking. Frye, 153 Ill. 2d at 33. As the defendants undertook to warn the decedent that Fiorinal may cause drowsiness, that constituted the extent of their undertaking and it was that undertaking that defendants were obliged to perform with reasonable care. 153 Ill. 2d at 34.\nThe supreme court determined that its construction of the defendants\u2019 voluntary undertaking was supported by public policy. The court explained, stating that \u201cif we were to hold that by choosing to place the \u2018drowsy eye\u2019 label on [the decedent\u2019s] prescription container defendants were assuming the duty to warn [the decedent] of all of Fiorinal\u2019s side effects, we believe that pharmacists would refrain from placing any warning labels on containers.\u201d 153 Ill. 2d at 33. The court concluded that this result would have the effect of depriving consumers of any warnings that might be beneficial. We agree with the supreme court\u2019s rationale.\nRelying primarily on the fact that in Frye the pharmacist undertook only to warn of one possible side effect whereas, here, Oseo listed various side effects, plaintiffs argue that the present case is distinguishable from Frye. Plaintiffs assert that the language on Osco\u2019s information sheet regarding whether there were any side effects to Daypro indicated an intent to describe all side effects and, therefore, the scope of Osco\u2019s undertaking was greater than that of the defendants in Frye.\nIn Frye the court determined that the duty of care to be imposed under the voluntary undertaking theory of liability was limited to the extent of the undertaking. In other words, the duty that the Frye court imposed upon pharmacists was that, when they warned of a possible side effect, the information provided should be accurate. In Frye one of the side effects of Fiorinal was that it caused drowsiness. Therefore, placing the \u201cdrowsy eye\u201d label on decedent\u2019s container was a proper warning and constituted the extent of the defendants\u2019 undertaking that they were obligated to perform with reasonable care.\nIn the present case, plaintiffs did not allege that the warnings provided by Oseo were inaccurate but, rather, that Oseo failed to warn of other side effects, i.e., possible renal failure or injury to kidneys. Under Frye the side effects listed by Oseo, constituted the extent of its undertaking. Had those warnings been inaccurate, e.g., had the information sheet stated, \u201cNo need to report eye/ear problems, change in urine color, bloody stools, difficulty breathing, mental changes,\u201d causing the consumer to ignore any of the warnings and, as a result, to suffer injury, Oseo would be liable for performing its voluntary undertaking negligently. However, such is not the situation here.\nIn the interest of the consumer, Kasin, Oseo provided several possible side effects of Daypro on its information sheet. By voluntarily undertaking to list some of the drug\u2019s side effects, Oseo did not assume a duty to list all possible side effects. Concluding otherwise would ignore the public policy considerations pointed out in Frye and would deter pharmacies from providing any information at all. Illinois case law has consistently held that public policy considerations may be taken into account by a court when determining if a duty has been voluntarily undertaken. Brown v. Walker Nursing Home, Inc., 307 Ill. App. 3d 721, 726 (1999).\nAs we find that Oseo did not voluntarily assume a duty to reveal all possible side effects of Daypro when it listed some of the side effects, plaintiffs cannot establish a foundational element of their negligence case and, therefore, summary judgment in Osco\u2019s favor was proper.\nAccordingly, the judgment of the circuit court of Lake County is affirmed.\nAffirmed.\nMcLAREN and COLWELL, JJ., concur.", "type": "majority", "author": "PRESIDING JUSTICE BOWMAN" } ], "attorneys": [ "Charles A. Cohn and Erwin Cohn, both of Cohn & Cohn, of Chicago, for appellants.", "Eric J. Parker, of Ridge, Ridge & Lindsay, of Waukegan, for appellee." ], "corrections": "", "head_matter": "CLARENCE KASIN et al., Plaintiffs-Appellants, v. OSCO DRUG, INC., Defendant-Appellee.\nSecond District\nNo. 2 \u2014 99 \u2014 0356\nOpinion filed April 12, 2000.\nCharles A. Cohn and Erwin Cohn, both of Cohn & Cohn, of Chicago, for appellants.\nEric J. Parker, of Ridge, Ridge & Lindsay, of Waukegan, for appellee." }, "file_name": "0823-01", "first_page_order": 843, "last_page_order": 849 }